Founded in 2010, Shenyang Wanbang Tiansheng Biotechnology Co., Ltd. (hereinafter referred to as WB Tiansheng) is an excellent group company dedicated in casing industry in China, with its business covering casing products and crude heparin sodium products and forming an industrial chain development. In August 2015, WB Tiansheng joined Jiangsu Wanbang Biopharmaceuticals (Group)(hereinafter referred to as Wanbang Biopharma) and became the core enterprise in the upstream supply chain of crude heparin sodium products. In December of the same year, it merged into Far-Eastern Casing Co., Ltd. (hereinafter referred to as Far-Eastern), and became a wholly-owned subsidiary of WB Tiansheng in April 2017, realizing embedded growth and outward expansion industrial development.

In 2019, WB Tiansheng achieved main business income of 212,724,000 RMB, tax revenue of 9,979,900 RMB, and the total assets of 132.247 million RMB.

For the future, WB Tiansheng will adhere to the brand concept of “Innovation for Good Health”, focusing on unmet medical needs, adheres to the "4 IN" strategy （Innovation, Internationalization, Integration and Intelligentization）and the development model of "endogenous growth, extensional expansion, and integrated development", and is committed to becoming a first-class enterprise in the domestic mainstream casing industry.